Helping improve patient outcomes and access to new medicines
Our expert team advises on commercial agreements for high cost and new drug purchases.
We advise a range of clients including NHS England when it enters into specialist and bespoke commercial arrangements relating to new and innovative high cost treatments that are not in routine commissioning.
These highly confidential commercial arrangements allow our clients to make the best possible treatments available to patients across the country whilst still delivering value for money. Pharmaceutical companies are also able to benefit from access to the world’s largest publicly funded health service.
Main Areas Of Practice
Our team regularly advises on commercial agreements for high cost and new drug purchases in the following areas:
Cancer Drugs Fund (CDF)
CDF allows for promising new cancer drugs to be made available to patients before they are fully approved for use in the NHS. These specialised agreements focus on keeping spend within the CDF budget and providing the evidence collection and data sharing arrangements necessary to assess if the drug can be moved into routine commissioning.
Budget Impact Test (BIT)
If the budget impact of a new drug exceeds NICE's threshold of £20 million, in any of the first three years, NHS England may engage in commercial discussions with the company. These discussions are designed to mitigate the impact that funding the technology would have on the rest of the NHS.
Clinical Priorities Advisory Group (CPAG)
CPAG assesses drugs, medical devices and treatments according to their clinical effectiveness, benefit for patients and value for money. We provide advice to NHS England about the commissioning of recommended services where they are likely to have a major budgetary impact.
Highly Specialised Technologies (HST)
HST are recommendations by NICE on the use of new and existing highly specialised medicines and treatments within the NHS in England. These medicines are often very high cost, low volume treatments where NHS England needs to enter into confidential commercial arrangements with the company in order to be able to make the treatments available to patients whilst delivering value for money to the NHS.
The 2019 Voluntary Scheme for Branded Medicines Pricing and Access (VPAS)
Our team have been advising on this new scheme which allows NHS England to offer more innovative commercial solutions to companies to enable new high cost drugs to be offered to more patients whilst delivering better value for money for the NHS and the taxpayer.
Related Expertise
Our Clients
Our expert team specialising in high cost and new drug procurement primarily advises the Specialised Commissioning Team within NHS England.
Highlights
Our Experts
BM Insights
Are you ready for the change in procurement? To help, we are running a our series of webinars on the subject. In this webinar on Thursday 5 December, the focus...
Read MoreWhat are the social value opportunities under the Procurement Act 2023? We are running a series of webinars on the changes in procurement and in this webinar on Thursday 3...
Read MoreMake sure that you are ready for the procurement changes with our series of webinars. In this webinar on Thursday 12 September, we will look at exclusion and debarment in...
Read MoreEnsure that you are set for change in procurement with our series of webinars. In this webinar on Thursday 6 June, the focus will be on standstill, challenges and remedies...
Read MoreTo help you get ready for change in procurement, we are running a series of webinars. In this webinar on Thursday 16 May, you will get a whistlestop tour of...
Read MoreGet ready for change with our series of webinars on procurement. In this webinar on Thursday 18 April, the focus will be on contracting authorities.
Read MoreNeed Advice?
Call 0238 085 7047
Or Fill in The Form
Our Experts are here to help